Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$3.21 +5.6%	$2.95	$0.40 ▼ $5.48	$71.57M	0.27	185,484 shs	143,490 shs
ELYM Eliem Therapeutics	$2.19 -2.7%	$1.48	$2.35 ▼ $11.55	$65.16M	-0.39	486,688 shs	645,753 shs
MRKR Marker Therapeutics	$1.29 +6.6%	$1.45	$0.95 ▼ $5.95	$15.66M	1.45	166,307 shs	101,555 shs
VRCA Verrica Pharmaceuticals	$5.47 -4.7%	$6.62	$3.82 ▼ $29.70	$54.22M	1.92	49,586 shs	50,701 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-1.62%	0.00%	+1.00%	+164.35%	+316.04%
ELYM Eliem Therapeutics	+11.39%	+38.04%	+49.01%	+85.95%	-62.99%
MRKR Marker Therapeutics	+4.31%	-3.20%	-23.42%	+6.14%	-65.72%
VRCA Verrica Pharmaceuticals	+3.24%	-6.67%	-20.50%	-6.16%	-80.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.3197 of 5 stars	0.0	3.0	0.0	0.0	1.7	0.8	0.0
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	3.6109 of 5 stars	3.8	2.0	0.0	3.9	2.0	0.0	0.0
VRCA Verrica Pharmaceuticals	4.5953 of 5 stars	3.1	5.0	0.0	4.7	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	920.67% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$80.00	1,362.52% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	148.16	N/A	N/A	$0.40 per share	8.03
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
MRKR Marker Therapeutics	$6.59M	2.53	N/A	N/A	$0.81 per share	1.59
VRCA Verrica Pharmaceuticals	$7.57M	6.83	N/A	N/A	($1.85) per share	-2.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.17	N/A	∞	N/A	-963.46%	-46.76%	-23.02%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
MRKR Marker Therapeutics	-$10.73M	-$1.37	N/A	N/A	N/A	-271.12%	-114.59%	-90.31%	N/A
VRCA Verrica Pharmaceuticals	-$76.58M	-$8.28	N/A	N/A	N/A	N/A	N/A	-115.48%	11/3/2025 (Estimated)

Latest MRKR, ELYM, VRCA, and ABVC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MRKR Marker Therapeutics	-$0.55	-$0.29	+$0.26	-$0.29	$0.72 million	$0.86 million
8/13/2025	Q2 2025	ABVC ABVC BioPharma	N/A	-$0.13	N/A	-$0.13	N/A	N/A
8/12/2025	Q2 2025	VRCA Verrica Pharmaceuticals	-$0.70	$0.02	+$0.72	$0.02	$4.37 million	$12.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.42	0.42
ELYM Eliem Therapeutics	N/A	60.41	60.41
MRKR Marker Therapeutics	N/A	3.45	6.79
VRCA Verrica Pharmaceuticals	N/A	1.26	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ELYM Eliem Therapeutics	69.76%
MRKR Marker Therapeutics	22.39%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
ELYM Eliem Therapeutics	4.70%
MRKR Marker Therapeutics	7.80%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	23.54 million	14.08 million	Not Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
MRKR Marker Therapeutics	60	12.94 million	11.93 million	Not Optionable
VRCA Verrica Pharmaceuticals	40	9.45 million	4.35 million	Optionable

MRKR, ELYM, VRCA, and ABVC Headlines

Recent News About These Companies

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Declines By 32.3%

August 22 at 3:25 AM | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Drops By 32.3%

August 22 at 2:11 AM | americanbankingnews.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

August 14, 2025 | marketbeat.com

Verrica Posts Profit in Fiscal Q2

August 14, 2025 | theglobeandmail.com

Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 13, 2025 | finanznachrichten.de

Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Verrica Pharmaceuticals Regains Nasdaq Compliance

August 12, 2025 | msn.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

August 12, 2025 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 12, 2025 | globenewswire.com

3VRCA : What to Expect from Verrica Pharmaceuticals's Earnings

August 11, 2025 | benzinga.com

Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

August 6, 2025 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of "Hold" from Brokerages

August 5, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0.2% - Should You Buy?

August 3, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Rises By 1,164.0%

August 2, 2025 | marketbeat.com

Verrica Pharmaceuticals Implements Reverse Stock Split

August 1, 2025 | theglobeandmail.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Gap Down - What's Next?

July 26, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...

July 12, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc News (VRCA) - Investing.com

July 11, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, ELYM, VRCA, and ABVC Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$3.21 +0.17 (+5.59%)

Closing price 04:00 PM Eastern

Extended Trading

$3.25 +0.04 (+1.25%)

As of 07:59 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Eliem Therapeutics NASDAQ:ELYM

$2.19 -0.06 (-2.67%)

As of 08/21/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Marker Therapeutics NASDAQ:MRKR

$1.29 +0.08 (+6.61%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 -0.01 (-0.70%)

As of 07:32 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Verrica Pharmaceuticals NASDAQ:VRCA

$5.47 -0.27 (-4.70%)

Closing price 04:00 PM Eastern

Extended Trading

$5.47 0.00 (0.00%)

As of 07:47 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time